Immunicum AB (publ) Publishes Prospectus in Connection with Rights Issue and Directed Issue
23 November 2018 - 9:15PM
Press Release
23 November 2018
NOT FOR RELEASE, DISTRIBUTION OR
PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES
OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN
WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE
UNLAWFUL.
Immunicum AB (publ) Publishes Prospectus in Connection with Rights
Issue and Directed Issue
The Extraordinary
General Meeting of Immunicum AB (publ) ("Immunicum" or the
"Company") on 8 November 2018 resolved, in accordance with the
Board's proposal from 16 October 2018, to implement a Rights Issue
for existing shareholders (the "Rights Issue") and a Directed Issue
(the "Directed Issue"). In connection with the Rights Issue and the
Directed Issue (the "Share Issues"), the Board has prepared a
prospectus that today, 23 November 2018, has been approved and
registered by Finansinspektionen (the Swedish Financial Supervisory
Authority) and subsequently published by the Company. The
prospectus, containing full terms and conditions, and subscription
forms are available on the Company's website (www.immunicum.se) as
well as on Erik Penser Bank AB's website www.penser.se.
The Share Issues
in Short
- The Share Issues will raise 351
MSEK before issue costs, assuming full subscription.
- The Directed Issue comprises
20,915,588 shares issued at a price of SEK 8.50 per share,
corresponding to a total of circa SEK 178M. The issue has mainly
been subscribed by a number of institutional investors including
the Fourth AP fund (SEK 38M), Gladiator, (SEK 32M), the Second AP
fund (SEK 21M), Alfred Berg (SEK 20M), Nordic Cross (SEK 17M) and
Adrigo (SEK 10M). In addition, a number of private investors have
subscribed for the Directed Issue including Rothesay (SEK 10M),
Lennart Sten through company (SEK 7.5M), EWS Stiftelsen (SEK 3M)
and JESEM AS (SEK 1M). Furthermore, a number of private investors
have subscribed for SEK 18M through Avanza Pension.
- The terms of the Rights Issue
imply that two (2) new shares are issued for each five (5) existing
shares, which implicates that up to 20,383,412 shares will be
issued under the Rights Issue at a price of SEK 8.50 per share,
corresponding to a total of circa SEK 173M.
- Rothesay Ltd has entered into a
subscription commitment in the Rights Issue of SEK 3.4M,
corresponding to approximately 2 percent of the Rights Issue. The
remaining share of the Rights Issue is covered by guarantee
commitments.
Time plan for the
Rights Issue
21 November, 2018
Record date
26 November - 6 December,
2018
Trading in subscription rights on Nasdaq Stockholm
26 November - 10 December,
2018
Subscription period
Around 13 December, 2018
Publication of the
outcome in the Rights Issue
Week 3, 2019
Estimated
registration of the Share Issues with Bolagsverket (the Swedish
Companies Registration Office)
Presentations
In connection with the Share Issues, the Company will present its
business plan on the following occasions:
- Stockholm, 26 November 2018,
Aktiespararna, Stora Aktiedagen - Notice to attend is to be made on
Aktiespararna's webiste www.aktiespararna.se
- Stockholm, 28 November 2018 at
Erik Penser Bank's Bolagsdag starting at 13:00 - Erik Penser Bank,
Apelbergsgatan 27, notice to attend shall be sent to
bolagsdag@penser.se
- Stockholm, 4 December 2018, lunch
presentation at Erik Penser Bank, 12:00 - Erik Penser Bank,
Apelbergsgatan 27, notice to attend shall be sent to
seminarium@penser.se
Financial,
Strategic and Legal Advisor
Erik Penser Bank is the financial advisor and Asperia AB is the
strategic advisor to Immunicum in connection with the Share Issues.
Furthermore, Advokatfirman Delphi is the legal advisor to the
Company in connection with the Share Issues.
This information
is information that Immunicum AB (publ) is obliged to make public
pursuant to the Financial Instruments Trading Act. The information
was submitted for publication at 11.15 am CET on 23 November
2018.
For more information, please contact:
Carlos de Sousa, CEO,
Immunicum
Telephone: +46 31 41 50 52
E-mail: info@immunicum.com
Michaela Gertz, CFO,
Immunicum
Telephone: +46 70 926 17 75
E-mail: ir@immunicum.com
Media Relations
Gretchen Schweitzer and Joanne
Tudorica
Trophic Communications
Telephone: +49 172 861 8540 or +49 892 388 7730
E-mail: ir@immunicum.com
About Immunicum AB (publ) Immunicum is establishing a unique
immuno-oncology approach through the development of allogeneic,
off-the-shelf cell-based therapies. Our goal is to improve survival
outcomes and quality of life by priming the patient's own immune
system to fight cancer. The company's lead product ilixadencel,
consisting of pro-inflammatory allogeneic dendritic cells, has the
potential to become a backbone component of modern cancer
combination treatments in a variety of solid tumor indications.
Founded and based in Sweden, Immunicum is publicly traded on the
Nasdaq Stockholm. www.immunicum.com
|
20181123_Immunicum_Prospectus Press
Release_ENG_Final
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Immunicum AB via Globenewswire
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Apr 2024 to May 2024
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From May 2023 to May 2024